In pancreatic cancer cells carrying KRAS mutations, the activation of nuclear factor erythroid 2-related factor 2 (NRF2) leads to upregulation of glycolysis, increased glutamine uptake, and reprogrammed glutaminolysis 89. Here, KRAS is linked to pancreatic neoplasm.